- Home
- SONN vs DYAI Comparison
SONN vs DYAI Comparison
Compare SONN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- DYAI
- Stock Information
- Founded
- SONN N/A
- DYAI 1979
- Country
- SONN United States
- DYAI United States
- Employees
- SONN N/A
- DYAI N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SONN Health Care
- DYAI Health Care
- Exchange
- SONN Nasdaq
- DYAI Nasdaq
- Market Cap
- SONN 32.4M
- DYAI 30.2M
- IPO Year
- SONN N/A
- DYAI 2004
- Fundamental
- Price
- SONN $4.02
- DYAI $0.96
- Analyst Decision
- SONN Strong Buy
- DYAI Strong Buy
- Analyst Count
- SONN 1
- DYAI 1
- Target Price
- SONN $20.00
- DYAI $3.00
- AVG Volume (30 Days)
- SONN 773.9K
- DYAI 132.8K
- Earning Date
- SONN 12-16-2025
- DYAI 11-12-2025
- Dividend Yield
- SONN N/A
- DYAI N/A
- EPS Growth
- SONN N/A
- DYAI N/A
- EPS
- SONN N/A
- DYAI N/A
- Revenue
- SONN $1,000,000.00
- DYAI $3,342,195.00
- Revenue This Year
- SONN $5,376.22
- DYAI $18.18
- Revenue Next Year
- SONN N/A
- DYAI $87.65
- P/E Ratio
- SONN N/A
- DYAI N/A
- Revenue Growth
- SONN 1689.52
- DYAI N/A
- 52 Week Low
- SONN $1.08
- DYAI $0.71
- 52 Week High
- SONN $19.30
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- SONN 44.01
- DYAI 43.62
- Support Level
- SONN $3.95
- DYAI $0.90
- Resistance Level
- SONN $5.06
- DYAI $1.00
- Average True Range (ATR)
- SONN 0.87
- DYAI 0.09
- MACD
- SONN -0.08
- DYAI 0.00
- Stochastic Oscillator
- SONN 18.83
- DYAI 47.50
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.